Dr. Sehn Discusses the Efficacy of the CD20 Agent GA101

Laurie H. Sehn, MD, MPH
Published: Sunday, Dec 11, 2011

Laurie H. Sehn, MD, MPH, clinical associate professor in the division of medical oncology at the University of British Columbia and the British Columbia Cancer Agency, discusses bioengineered monoclonal antibodies and their promising future in treating patients with lymphoma. At the 53rd Annual Meeting of the American Society of Hematology, held in San Diego, Sehn presented phase II data on GA101, a monoclonal antibody that targets CD20, and how it might perform even better than rituximab, a practice-changing therapy for patients with non-Hodgkin lymphoma.

Laurie H. Sehn, MD, MPH, clinical associate professor in the division of medical oncology at the University of British Columbia and the British Columbia Cancer Agency, discusses bioengineered monoclonal antibodies and their promising future in treating patients with lymphoma. At the 53rd Annual Meeting of the American Society of Hematology, held in San Diego, Sehn presented phase II data on GA101, a monoclonal antibody that targets CD20, and how it might perform even better than rituximab, a practice-changing therapy for patients with non-Hodgkin lymphoma.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x